Clinical observatiaon of lobaplatin plus etoposide in the treatment of esophageal small cell of carcinoma

VernacularTitle:洛铂联合依托泊苷治疗初治食管小细胞癌的疗效观察
Author: Zhili WU ; Lin LU ; Yan LI ; Xuezhu SUN
Publication Type:Journal Article
Keywords: Lobaplation; Etoposide; Chemotherapy; Esophageal small cell of carcinoma
From: Chinese Journal of Primary Medicine and Pharmacy 2015;(16):2470-2472
CountryChina
Language:Chinese
Abstract: Objective To observe curative effect of lobaplatin plus etoposide,the new antitumor platinum drugs,on the untreated esophageal small cell of carcinoma.Methods Sixteen patients with esophageal small cell of carcinoma were treated using the lobaplatin/vp16 regimen.Results The complete response (CR) rates were 31.3%,partial response (PR)rates were 37.5%,stable disease (SD)rates were 25%,progressive disease (PD) rates were 6.25%,overall response rate (ORR)68.8%.Languor was the most common symptom in the grade -ⅠtoⅣ adverse reactions.All patients had symptoms of languor.Other related symptoms included the anaemia (41.7%), leukocytopenia (39.7%),thrombocytopenia (20.9%),anorexia,vomiting,nausea (29.3%)and increase of ALT and AST (14.5%).The toxic effect was not serious damage.Conclusion Lobaplatin is a new and safe antitumor platinum drug with a promising clinical effect,has a good tolerance in patients,and it can try to be used in the patients who have esophageal small cell of carcinoma.